Sugi Predict

Sugi Predict / Targets / TEC

TEC

Tyrosine-protein kinase Tec · P42680 · TEC on Sugi Atlas →

46,723 patent compounds predicted against TEC, 39,124 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL123348 SCHEMBL123348 1.00 3/20
SCHEMBL123351 SCHEMBL123351 0.81 3/20
SCHEMBL123062 SCHEMBL123062 0.81 3/20
SCHEMBL124479 SCHEMBL124479 0.79 3/20
SCHEMBL123779 SCHEMBL123779 0.78 3/20
SCHEMBL148535 SCHEMBL148535 0.76 3/20
SCHEMBL122287 SCHEMBL122287 0.75 3/20
SCHEMBL123582 SCHEMBL123582 0.75 3/20
SCHEMBL147980 SCHEMBL147980 0.75 3/20
SCHEMBL149296 SCHEMBL149296 0.74 3/20
SCHEMBL124380 SCHEMBL124380 0.72 3/20
SCHEMBL122291 SCHEMBL122291 0.71 3/20
SCHEMBL124379 SCHEMBL124379 0.70 3/20
SCHEMBL122276 SCHEMBL122276 0.70 3/20
SCHEMBL122294 SCHEMBL122294 0.70 3/20
SCHEMBL123818 SCHEMBL123818 0.69 3/20
SCHEMBL147342 SCHEMBL147342 0.68 3/20
SCHEMBL123462 SCHEMBL123462 0.58 3/20
SCHEMBL123056 SCHEMBL123056 1.00 2/20
SCHEMBL123345 SCHEMBL123345 0.80 2/20

Clinical trials — most relevant to TEC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma PHASE2UNKNOWN
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia PHASE2RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells PHASE2UNKNOWN
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. PHASE1/PHASE2UNKNOWN
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML PHASE2COMPLETED
EGF Ointment for Erlotinib Skin Lesion PHASE2COMPLETED
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer PHASE2COMPLETED
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL PHASE1/PHASE2RECRUITING
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma PHASE2RECRUITING
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer PHASE1/PHASE2WITHDRAWN
A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults PHASE1COMPLETED
A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers PHASE1COMPLETED
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas PHASE1COMPLETED
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies PHASE1ACTIVE_NOT_RECRUITING
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) nanWITHDRAWN
Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. nanACTIVE_NOT_RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes nanCOMPLETED
A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TEC binder may also engage these)

ProteinNameSimilarity
P24604 — 0.998 P24604 →
ITK Tyrosine-protein kinase ITK/TSK 0.996 landscape →
P35991 — 0.995 P35991 →
TXK Tyrosine-protein kinase TXK 0.995 landscape →
BTK Tyrosine-protein kinase BTK 0.992 landscape →
Q0VBZ0 — 0.989 Q0VBZ0 →
P41241 — 0.988 P41241 →
Q8JH64 — 0.988 Q8JH64 →
P42682 — 0.988 P42682 →
Q03526 — 0.987 Q03526 →
FRK Tyrosine-protein kinase FRK 0.987 landscape →
P42690 — 0.986 P42690 →
P00528 — 0.985 P00528 →
Q9V9J3 — 0.985 Q9V9J3 →
BMX Cytoplasmic tyrosine-protein kinase BMX 0.985 landscape →
P63185 — 0.985 P63185 →
P41239 — 0.985 P41239 →
P32577 — 0.985 P32577 →
CSK Tyrosine-protein kinase CSK 0.985 landscape →
P17713 — 0.984 P17713 →
Q54Y55 — 0.983 Q54Y55 →
P08630 — 0.983 P08630 →
P31693 — 0.983 P31693 →
P10936 — 0.983 P10936 →
YES1 Tyrosine-protein kinase Yes 0.983 landscape →
Q60629 — 0.982 Q60629 →
G5EE56 — 0.982 G5EE56 →
P00526 — 0.982 P00526 →
P50545 — 0.982 P50545 →
Q28923 — 0.981 Q28923 →